Roche posts SKYSCRAPER-01 results for tiragolumab/atezolizumab; registers Phase II Parkinson's trialNov 13Weekly roundup, 9 itemsalectinibastegolimab
Roche registers giredestrant Phase 3 trial; six other studies updateNov 6Weekly roundup, 16 itemsAbbViealectinibUpdated
FDA grants accelerated approval to Rybrevant Faspro for head and neck cancerNov 5Regulatory decisionamivantamab and hyaluronidase-lpujamivantamab-vmjw
IDEAYA completes darovasertib NDA, halts Phase 3 OptimUM-010 for enrollment issuesNov 3Quarterly updateAlector, Inc.Allogene Therapeutics
AbbVie posts KEEPsAKE 2 update; registers pediatric vitiligo and real-world MIRV studiesOct 29Weekly roundup, 7 itemsABBV-706ABBV-722Updated
Wave Life Sciences details Q3 2026 progress on WVE-006, WVE-007, WVE-008 pipelineOct 28Quarterly updateBristol Myers SquibbEli LillyUpdated
Oncolytics reports durability and survival data for pelareorep in anal cancerOct 27Regulatory decisionOncolytics Biotechpelareorep
Zai Lab raises $250 million via private placement, discloses new zoci dataOct 23FinancingZai Lab (Shanghai) Co., Ltd.
Genentech lists Phase Ib KRAS G12D trial; Roche-sponsored DLBCL study shows updateOct 9Weekly roundup, 9 itemsalectinibcisplatinUpdated
FDA clears atezolizumab combo for Stage III dMMR colon cancerOct 8Regulatory decisionatezolizumabatezolizumab and hyaluronidase-tqjs
Genentech gets two ROZLYTREK label updates; Roche's IMvigor011, forimtamig results standOct 2Weekly roundup, 13 itemsafimkibartatezolizumabUpdated
Inovio's UCa-001 trial completes; results posted for INO-5401 combo in urothelial carcinomaSep 2Trial updateINO-5401INO-9012
Adagene reports mid-2026 results, muzastotug data across CRC and HCC trialsAug 12Quarterly updateAdagene Inc
Roche results post for two terminated Morpheus umbrella trials; new Phase 1/2 studies registeredAug 7Weekly roundup, 6 itemsatezolizumabBioLineRx, Ltd.
Exelixis Q2 2026 results detail zanzalintinib pipeline progress, narrows guidanceAug 5Quarterly updateExelixisMerck & Co., Inc.
Boehringer Ingelheim registers Phase Ib/II trial pairing obrixtamig with Zai Lab's ZL-1310 in SCLCJul 16Trial updateBoehringer IngelheimZai Lab (Shanghai) Co., Ltd.